Syndax reports entinostat data in NSCLC
Syndax Pharmaceuticals Inc. (Waltham, Mass.) said entinostat plus Tarceva erlotinib missed the primary endpoint of significantly improving the 4-month progression-free survival rate vs. placebo plus Tarceva in the Phase II ENCORE 401 trial to treat advanced non-small cell lung cancer (NSCLC). Entinostat plus Tarceva also non-significantly improved median PFS and overall survival vs. placebo plus Tarceva. In a subgroup of patients with elevated expression of E-cadherin ( CDH1; CD324), a molecular marker of epithelial tumors, the combination significantly improved median overall survival vs. placebo (9.4 vs. 5.4 months, p=0.03), and non-significantly improved median PFS (3.7 vs. 1.9 months, p=0.19). Data were presented at American Society for Radiation Oncology meeting in Chicago. The double-blind, U.S. trial included 132 evaluable patients. ...